The acquisition is complete, APLS shares are delisted and no longer trade. Holders who tendered will receive $41.00 cash plus CVRs. The CVRs are non-transferable and trade only via limited permitted transfers; monitor SYFOVRE sales trajectories for potential milestone triggers. Note holders should evaluate conversion vs. repurchase options by June 29, 2026.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK AT ENTRY AT T+1- T+0 · May 14 $41.03entry
- T+1 · 6mo ago 0.00%α +1.23% · $41.03
- T+5 · due 6mo ago Pending
- T+20 · due 5mo ago Pending
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Biogen completed its acquisition of Apellis Pharmaceuticals on May 14, 2026, through a tender offer and subsequent merger. Apellis stockholders received $41.00 per share in cash plus one contingent value right (CVR) per share, with potential milestone payments of up to $4.00 per CVR tied to SYFOVRE sales targets. The deal valued at approximately $5.3 billion, and APLS common stock has been delisted from Nasdaq, with the company now a wholly owned subsidiary of Biogen.
Key Financial Metrics
Key Facts
- Biogen completed acquisition of Apellis for $41.00 per share in cash plus one CVR per share (up to $4.00 additional per CVR tied to SYFOVRE sales milestones).
- Total deal value approximately $5.3 billion, excluding potential CVR payments.
- 105,687,831 shares (82.4% of outstanding) were validly tendered in the offer.
- CVR milestones: $2.00 per CVR if SYFOVRE annual net sales reach $1.5B in 2027-2030; $2.00 per CVR if sales reach $2.0B in 2027-2031 (or $4.00 if first milestone missed but second achieved in 2031).
- Biogen estimates maximum CVR payout of approximately $582 million if all milestones achieved.
- APLS common stock delisted from Nasdaq; company now a wholly owned subsidiary of Biogen.
- All directors resigned; Michael Dambach appointed as sole director.
- Convertible notes (3.500% due 2026) converted to cash and CVRs; holders have repurchase right at ~$1,008.46 per $1,000 principal.
Financial Impact
Total deal value ~$5.3B cash plus up to ~$582M in potential CVR payments (max ~$4.00/share).
Risk Factors
- CVR milestones may not be achieved; maximum payout requires SYFOVRE annual sales of $1.5B-$2.0B by 2030-2031.
- CVRs are non-transferable and illiquid, no secondary market.
- Convertible note holders face complex election between conversion (cash + CVRs) and repurchase at ~$1,008.46/principal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222923 |
| Document: d23709d8k.htm | 0001193125-26-222923 |
| Document: d23709dex32.htm | 0001193125-26-222923 |
| Document: d23709dex31.htm | 0001193125-26-222923 |
| Document: d23709dex991.htm | 0001193125-26-222923 |
| Document: d23709dex41.htm | 0001193125-26-222923 |
| Document: 0001193125-26-222923-index-headers.html | 0001193125-26-222923 |
| Document: 0001193125-26-222923-index.html | 0001193125-26-222923 |
| Document: 0001193125-26-222923.txt | 0001193125-26-222923 |
Track record
5 reports on APLS
Filters
- May 26, 202624w ago 15-12G Neutral 6/10 No price data
- May 14, 202626w ago 25-NSE Neutral 2/10 Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
- May 14, 202626w ago 8-K Bullish 8/10 Viewing Entry $41.03 to $41.03 · 0.00% +1.23% vs SPY
- May 4, 202628w ago 8-K Neutral 2/10 Entry $40.97 to $40.97 · 0.00% −0.80% vs SPY
- Mar 27, 202633w ago Institutional Cluster Mixed 6/10 Entry $16.97 to $17.09 ▲ +0.71% +1.06% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers